BioSante reported that with 2, 869 women enrolled and over 3, 000 women-years of exposure in it LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent.

FORBES: BioSante's Pollyannish Press Release